Medway Community Healthcare Medway NHS Trust Foundation Trust
Medway Clinical Commissioning Group Swale Clinical Commissioning Group

2022 Kent & Medway Medicines Optimisation Newsletters

 Kent and Medway Medicines Optimisation Newsletters For 2022

Kent & Medway Medicines Optimisation team produce a monthly newsletter highlighting prescribing information together with local and national health information. 

You can view or download copies of our newsletters

 

Issue Date Article
Issue 41 Click Here  Dec 22
  • HSJ Awards Success
  • OTC prescribing
  • COPD inhaler guidance reminder
  • Discontinuation of Stemetil 5mg/5ml Syrup
  • Asthma and nebulisers
  • All Ranitidine products – license suspended
  • Shortages Summary December 2022
  • MHRA Updates
  • NICE News December 2022
Issue 40 Click Here  Nov 22

• Sodium Valproate Reminder
• Notification of product name change: Carefine Insulin Pen Needles
• SPS Medicines Advice Service Information
• MHRA Update & Yellow Card Reporting
• NHS England: Direct Oral Anticoagulants (DOAC) infographic link
• FreeStyle Libre 1 Discontinuation
• Shortages
• Serious Shortage Protocols: Estraderm MX® 50mcg and 75mcg patches
• Discontinuation of Stemetil 5mg/5ml
• MHRA Class 4 Medicines Defect : Venlafaxine XL 300 mg prolonged-release tablets

Issue 39 Click Here Oct 22 • Guidance on NHS patients who wish to pay for additional private care
• Colchicine Prescribing
• Kent and Medway Position Statement and Risk Mitigation Principles for Anticoagulant Prescribing
• Ardens Long Term Conditions training webinar
• Medicines Optimisation MHRA Drug Safety Update – September 2022 (for October 2022 MO Newsletter)
• Shortages Summary October 2022
• Medicine Supply Notifications: Nafarelin, Dulaglutide, Semaglutide and Dioralyte
• Asthma inhalers and the Environment Patient Decision Aid (NG80)
• MHRA Anti-epileptic drugs: Advice on switching between manufacturer’s products.
• World Anti-Microbial Awareness Week 2022 (WAAW)
• Revised SPC: Forxiga (dapagliflozin) film-coated tablets
• PrescQipp Award Success
• CPCS Request for Support from Practices
• Pharmacy Technicans Day- 18th October 2022
Issue 38 Click Here Sep 22 • Clozapine Safety
• Product Discontinuation: Seroxat (paroxetine hydrochloride) 20mg/10ml oral suspension
• Product Discontinuation: Insuman Infusat 100units/ml solution for injection 3.15ml catridges (Sanofi) 5 cartridge
• Amoxicillin Prescribing and Duration
• Reminder: Best Practice Guidance for Care Homes
• Medicines Optimisation MHRA Drug Safety Update – August 2022 (for September 2022 MO Newsletter)
• Shortages Summary September 2022
• Medicine Supply Notification – Temazepam 10mg and 20mg tablets – and Local Recommendations
• MHRA – Class 4 Medicines Defect Information: Rosuvastatin 5 mg, 10 mg and 20 mg film-coated tablets EL (22)A/35
• MHRA – Class 4 Medicines Defect Information: Rosemont Pharmaceuticals Ltd, Atorvastatin 4mg/ml Oral Suspension & Sildenafil 10mg/ml Oral Suspension, EL (22)A/39
• MHRA – Class 2 Medicines Recall: Dysport 500 Units Powder for Solution for Injection, EL (22)A/36
• MHRA – Class 2 Medicines Recall: Novartis Pharmaceutical UK, Sandimmun Oral Solution, EL (22)A/40
Issue 37 Click Here Aug 22
  • Guidance for Multicompartmental Aids MCAs/Dosette Boxes
  • Shortages Summary August 2022
  • National Patient Safety Alert: Mexiletine
  • MHRA Drug Safety Update
  • MHRA Class 4 Medicines Defect Information: Novo Nordisk Limited, NovoRapid® FlexTouch® 100 units/ml, Saxenda® FlexTouch® (liraglutide) 6mg/ml, EL(22)A/33
  • CPD conference on Controlled Drugs: Ensuring the Safer Management
  • Important Product Supply Information: Shortec Oral Solution
  • NICE News Bimonthly - August 2022
  • Cow’s Milk Allergy Feed
  • Tobacco Industry Lobbying
Issue 36 Click Here Jul 2022
  • Hypomagnesaemia associated with Proton Pump Inhibitors (PPIs)
  • Inadvertent Oral Administration of Potassium Permanganate Alert
  • Asthma and Nebulisers
  • Dapagliflozin for treating Chronic Kidney Disease (CKD)
  •  Managing Deterioration Management tool – RESTORE2
  • Best Practice Guidance for Care Homes
Issue 34 - 35 Click Here Jun 2022
  • The Carbon Footprint of Inhalers
  • Position Statement and Risk Mitigation Principles for Anticoagulant prescribing
  • Loprazolam 1mg Tablets - Orifarm UK Ltd, MHRA - Class 4 Medicines Defect 
Issue 33 Click Here 28/04/22
  • Potassium Permanganate: Inadvertent Oral Administration
  • South East Lipids Webinar
  • Hepatitis: increase in acute cases of unknown aetiology in children
  • NHS National Summary Guidance for Lipid Management for K&M
  • Prescribers link Code to Practices (Registration and Removal from practices)
  • CPPE e-learning – ‘Controlled Drugs in Chronic Pain’
  • Provision of Lymphodema Garments
  • Solriamfetol in Primary Care
  • Pregabalin (Lyrica): findings of safety study on risks in pregnancy
Issue 32 Click Here 24/03/22
  • New NHS E System for Recording Patient Safety Events
  • New Guidance - BPSD Primary Care & Care Homes Best Practice
  • NICE Update for Lokelma
  • Dapagliflozin EMIS search to support MHRA alert
  • Reminder- Saxenda
  • Learning from Incidents- Allopurinol / Azathioprine Interaction
  • Inclisiran – Information on funding and supply
  • Edoxaban – New PCN DES IIF Indicators
  • New Adult Autism and ADHD Servic
Issue 31 Click Here 24/02/22
  • Molnupiravir swallowing difficulties
  • Kent and Medway Position on carbon footprint
  • Medicines Optimisation Scheme Survey
  • Formulary UpdateKent and Medway COPD Guidance for primary care
  • Product Recalls for Alimentum® & Elecare®
  • Implementation Guidance for NICE TA 694
  • Mirabegron Prescribing
  •  NICE Publication updates 

 

Issue 30 Click Here 27/01/22
  • COVID Vaccine Allergy Pathway Update
  •  Dapagliflozin (Forxiga) MHRA Safety Update
  • Updated DOAC Monitoring Recommendations in NVAF
  • Medicines Supply Tool
  • Adrenaline Auto Injectors COPD Rescue Packs
  • Formulary Update: Triple Therapy Inhalers for asthma
  • Kent & Medway Palliative Care Chart
  • Prescqipp Resources
  • Benzodiazepines and Z Drugs Webinar
  • MHRA Alerts (see MHRA Drug Safety update)

 

  • First Line Choice
  • On Formulary
  • Specialist Initiation Only
  • Hospital Only
  • KMPT Initiation Only
  •